These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35477876)

  • 1. Rationale design and efficacy of a smartphone application for improving self-awareness of adherence to edoxaban treatment: study protocol for a randomised controlled trial (adhere app).
    Kim IC; Lee JH; Choi DJ; Park SJ; Lee JH; Park SM; Kim M; Kim HL; Lee S; Kim IJ; Choi S; Bang J; Ali B; Hussain M; Ali T; Lee S
    BMJ Open; 2022 Apr; 12(4):e048777. PubMed ID: 35477876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ReInforcement of adherence via self-monitoring app orchestrating biosignals and medication of RivaroXaban in patients with atrial fibrillation and co-morbidities: a study protocol for a randomized controlled trial (RIVOX-AF).
    Yoon M; Park JJ; Hur T; Hua CH; Shim CY; Yoo BS; Cho HJ; Lee S; Kim HM; Kim JH; Lee S; Choi DJ
    Front Cardiovasc Med; 2023; 10():1130216. PubMed ID: 37324622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Smartphone App to Improve Oral Anticoagulation Adherence in Patients With Atrial Fibrillation: Prospective Observational Study.
    Senoo K; Miki T; Ohkura T; Iwakoshi H; Nishimura T; Shiraishi H; Teramukai S; Matoba S
    JMIR Mhealth Uhealth; 2022 Jan; 10(1):e30807. PubMed ID: 34894626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MEDication reminder APPs to improve medication adherence in Coronary Heart Disease (MedApp-CHD) Study: a randomised controlled trial protocol.
    Santo K; Chow CK; Thiagalingam A; Rogers K; Chalmers J; Redfern J
    BMJ Open; 2017 Oct; 7(10):e017540. PubMed ID: 28993388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acceptability and feasibility of the NPS MedicineWise mobile phone application in supporting medication adherence in patients with chronic heart failure: Protocol for a pilot study.
    Chapman-Goetz J; Packham N; Gabb G; Potts C; Yu K; Prosser A; Hotham E; Suppiah V
    PLoS One; 2022; 17(2):e0263284. PubMed ID: 35120174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE-AF Randomized Clinical Trial.
    Kuroda M; Tamiya E; Nose T; Ogimoto A; Taura J; Imamura Y; Fukuzawa M; Hayashi T; Akao M; Yamashita T; Lip GYH; Okumura K
    JAMA Cardiol; 2022 Jun; 7(6):583-590. PubMed ID: 35416910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
    Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
    Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of a Smartphone App-Based Intervention With Bluetooth-Connected Monitoring Devices and a Feedback System in Heart Failure (SMART-HF Trial): Randomized Controlled Trial.
    Yoon M; Lee S; Choi JY; Jung MH; Youn JC; Shim CY; Choi JO; Kim EJ; Kim H; Yoo BS; Son YJ; Choi DJ
    J Med Internet Res; 2024 Apr; 26():e52075. PubMed ID: 38683665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protocol for Home-Based Solution for Remote Atrial Fibrillation Screening to Prevent Recurrence Stroke (HUA-TUO AF Trial): a randomised controlled trial.
    Wong CK; Hai JJ; Lau YM; Zhou M; Lui HW; Lau KK; Chan KH; Mok TM; Liu Y; Feng Y; Tan N; Tam WC; Tam KC; Feng X; Zuo ML; Yin LX; Tan J; Zhang WJ; Jiang X; Huang X; Ye J; Liang Y; Jiang W; Lei Z; Huang D; Yue WS; Tan G; Yan BP; Evora MA; Chen JY; Siu CW
    BMJ Open; 2022 Jul; 12(7):e053466. PubMed ID: 35840293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
    Skjøth F; Larsen TB; Rasmussen LH; Lip GY
    Thromb Haemost; 2014 May; 111(5):981-8. PubMed ID: 24577485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and design of the Atrial Fibrillation health Literacy Information Technology Trial: (AF-LITT).
    Guhl EN; Schlusser CL; Henault LE; Bickmore TW; Kimani E; Paasche-Orlow MK; Magnani JW
    Contemp Clin Trials; 2017 Nov; 62():153-158. PubMed ID: 28923492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
    Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
    Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
    Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
    Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
    De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Reimitz PE; Kirchhof P;
    J Cardiovasc Med (Hagerstown); 2019 Feb; 20(2):97-104. PubMed ID: 30540648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).
    De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Kerschnitzki M; Reimitz PE; Kirchhof P;
    BMC Cardiovasc Disord; 2019 Jul; 19(1):165. PubMed ID: 31299906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protocol, rationale and design of DAbigatran for Stroke PreVention In Atrial Fibrillation in MoDerate or Severe Mitral Stenosis (DAVID-MS): a randomised, open-label study.
    Zhou M; Chan EW; Hai JJ; Wong CK; Lau YM; Huang D; Lam CC; Tam CCF; Wong YTA; Yung SYA; Chan KWK; Feng Y; Tan N; Chen JY; Yung CY; Lee KL; Choi CW; Lam H; Ng A; Fan K; Jim MH; Yiu KH; Yan BP; Siu CW
    BMJ Open; 2020 Sep; 10(9):e038194. PubMed ID: 32978200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving pain treatment with a smartphone app: study protocol for a randomized controlled trial.
    Suso-Ribera C; Mesas Á; Medel J; Server A; Márquez E; Castilla D; Zaragozá I; García-Palacios A
    Trials; 2018 Feb; 19(1):145. PubMed ID: 29482614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study.
    Okumura K; Lip GYH; Akao M; Tanizawa K; Fukuzawa M; Abe K; Akishita M; Yamashita T
    Am Heart J; 2017 Dec; 194():99-106. PubMed ID: 29223441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. App to support Recovery in Early Intervention Services (ARIES) study: protocol of a feasibility randomised controlled trial of a self-management Smartphone application for psychosis.
    Steare T; O'Hanlon P; Eskinazi M; Osborn D; Lloyd-Evans B; Jones R; Rostill H; Amani S; Johnson S
    BMJ Open; 2019 Mar; 9(3):e025823. PubMed ID: 30898825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled trial of medication adherence and management of risk factors for secondary prevention of stroke (MaMoRS) using a smartphone-based application.
    Babu V; Sylaja PN; Soman B; Varma RP; Ms M; Gl G; Kumar B S
    Int J Stroke; 2024 Jul; 19(6):654-664. PubMed ID: 38533606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.